These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34645285)

  • 21. Does Emergency Medical Services Transportation Mitigate Post-stroke Discharge Disability? A Prospective Observational Study.
    Xirasagar S; Wu Y; Heidari K; Zhou J; Tsai MH; Hardin JW; Wronski R; Hurley D; Jauch EC; Sen S
    J Gen Intern Med; 2020 Nov; 35(11):3173-3180. PubMed ID: 32869194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke: The ENCHANTED Trial.
    Chen X; Wang X; Delcourt C; Li J; Arima H; Hackett ML; Robinson T; Lavados PM; Lindley RI; Chalmers J; Anderson CS;
    Stroke; 2020 Feb; 51(2):588-593. PubMed ID: 31822251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of the Cincinnati Prehospital Stroke Scale for identifying thrombolytic candidates in acute ischemic stroke.
    You JS; Chung SP; Chung HS; Lee HS; Park JW; Kim HJ; Lee SH; Park I; Lee HS
    Am J Emerg Med; 2013 Dec; 31(12):1699-702. PubMed ID: 24055479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early hospital arrival improves outcome at discharge in ischemic but not hemorrhagic stroke: a prospective multicenter study.
    Naganuma M; Toyoda K; Nonogi H; Yokota C; Koga M; Yokoyama H; Okayama A; Naritomi H; Minematsu K
    Cerebrovasc Dis; 2009; 28(1):33-8. PubMed ID: 19420920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
    Dong Y; Han Y; Shen H; Wang Y; Ma F; Li H; Wang Y; Dong Q
    Stroke Vasc Neurol; 2020 Dec; 5(4):348-352. PubMed ID: 32611728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy.
    Toyoda K; Inoue M; Yoshimura S; Yamagami H; Sasaki M; Fukuda-Doi M; Kimura K; Asakura K; Miwa K; Kanzawa T; Ihara M; Kondo R; Shiozawa M; Ohtaki M; Kamiyama K; Itabashi R; Iwama T; Aoki J; Minematsu K; Yamamoto H; Koga M;
    Stroke; 2021 Jan; 52(1):12-19. PubMed ID: 33297866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.
    Takagi T; Kato T; Sakai H; Nishimura Y
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):69-74. PubMed ID: 23164483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
    Zhu Z; Fu Y; Tian D; Sun N; Han W; Chang G; Dong Y; Xu X; Liu Q; Huang D; Shi FD
    Circulation; 2015 Sep; 132(12):1104-1112. PubMed ID: 26202811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials.
    Bivard A; Huang X; McElduff P; Levi CR; Campbell BC; Cheripelli BK; Kalladka D; Moreton FC; Ford I; Bladin CF; Davis SM; Donnan GA; Muir KW; Parsons MW
    Circulation; 2017 Jan; 135(5):440-448. PubMed ID: 27965285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
    Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
    Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
    Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
    BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
    Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of modified TAN score in predicting prognosis in patients with acute ischemic stroke undergoing endovascular therapy.
    Baydemir R; Aykaç Ö; Acar BA; Kocabaş ZU; Milanlioğlu A; Eryildiz ES; Özdemir AÖ
    Clin Neurol Neurosurg; 2021 Nov; 210():106978. PubMed ID: 34653924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke.
    van den Berg LA; Berkhemer OA; Fransen PSS; Beumer D; Lingsma H; Majoie CBM; Dippel DWJ; van der Lugt A; van Oostenbrugge RJ; van Zwam WH; Roos YB; Dijkgraaf MGW;
    Stroke; 2022 Mar; 53(3):968-975. PubMed ID: 34645287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reperfusion Therapy Frequency and Outcomes in Mild Ischemic Stroke in the United States.
    Saber H; Khatibi K; Szeder V; Tateshima S; Colby GP; Nour M; Jahan R; Duckwiler G; Liebeskind DS; Saver JL
    Stroke; 2020 Nov; 51(11):3241-3249. PubMed ID: 33081604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal.
    Nepal G; Yadav JK; Basnet B; Shrestha TM; Kharel G; Ojha R
    BMC Neurol; 2019 Jul; 19(1):155. PubMed ID: 31288770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of an emergency medicine pharmacist on door to needle alteplase time and patient outcomes in acute ischemic stroke.
    Barbour J; Hushen P; Newman GC; Vidal J
    Am J Emerg Med; 2022 Jan; 51():358-362. PubMed ID: 34823191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
    Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
    J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.